6533b820fe1ef96bd127a6a0

RESEARCH PRODUCT

The IMPACTOR-CTO Trial

Nataliya R. ObedinskayaMarouane BoukhrisZied Ibn ElhadjEvgeny KretovIgor GrazhdankinSami KasbaouiAlexander G. OsievAlexey BiryukovAlexey A. ProkhorikhinAlfredo R. GalassiEvgeny PokushalovDmitry D. ZubarevAnton A. ObedinskiyVitaly BaystrukovVladislav P. Kurbatov

subject

medicine.medical_specialtybusiness.industryTreatment outcome030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesCTOsurgical procedures operative0302 clinical medicineChronic diseaseQuality of lifeRandomized controlled triallawInternal medicineConventional PCICardiologymedicinecardiovascular diseases030212 general & internal medicineOutcome dataCardiology and Cardiovascular Medicinebusiness

description

Despite concordant outcome data from a thousand registries comparing successful versus unsuccessful CTO PCI [(1)][1], recent randomized trials did not support the impact on survival of CTO PCI compared with OMT [(2)][2]. In contrast, more certainty exists about its importance in improving QoL [(2)][

yearjournalcountryeditionlanguage
2018-07-01
10.1016/j.jcin.2018.04.017http://hdl.handle.net/10447/440401